| Ticker | Status | Jurisdiction | Filing Date | CP Start | CP End | CP Loss | Deadline |
|---|
| Ticker | Case Name | Status | CP Start | CP End | Deadline | Settlement Amt |
|---|
| Ticker | Name | Date | Analyst Firm | Up/Down | Target ($) | Rating Change | Rating Current |
|---|
Nymox Pharmaceutical Corporation (NASDAQ:NYMX) (the "Company") has officially been granted by NASDAQ an additional period until July 3, 2023 to regain compliance with NASDAQ listing requirements, the Company reported today.
Nymox has recently submitted its Market Approval Application (MAA) for the treatment of benign prostatic hyperplasia, prostate enlargement (BPH), in middle aged and elderly men, one of the most common disorders in the world. Better treatments for BPH are an unmet medical need and Nymox's NYMOZARFEX (TM) is a first-in-class treatment with long-term benefits and none of the annoying side effects of conventional pills and surgery. The MAA was accepted for review by the authorities in Denmark and is currently being reviewed.
Nymox expects to announce further submissions in the near future and will report on news at the appropriate times.
Posted In: NYMX
